Document Title: Beta Drugs Limited Joint Venture Announcement for Algeria Oncology Operations

Summary of Key Information:

Reporting Period (Quarter/Year): Not Specified

Nature of Filing / Announcement: Outcome of Board Meeting - Joint Venture Agreement

Date of Board Meeting / Approval: November 19, 2026

Audit Opinion: Not Specified

Auditor's Comment: Not Specified

Key Financial Highlights:

Standalone Results: Not Specified

Consolidated Results: Not Specified

Segment-wise Performance: Not Specified

Corporate Actions:

  • Approved entry into joint venture agreement with IMGSA Groupe SPA of Algeria
  • Joint venture company to be named IMGSA Oncologie SPA (to be incorporated in Algeria)
  • Joint venture purpose: manufacturing and marketing of oncology pharmaceutical products in Algeria
  • Ownership structure: Beta Drugs Limited - 49%, IMGSA Groupe SPA - 51%
  • Total investment in JV: USD 8.7 Million
  • Beta's investment: USD 3 million cash over 3 years plus technology transfer valued at USD 1.26 million
  • IMGSA's contribution: USD 4.43 million in form of plant and machinery transfer
  • JV will take over existing Oncology Plant currently owned by IMGSA

Regulatory Disclosures:

  • Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 referenced
  • Transaction does not qualify as related party transaction pre-incorporation
  • JV will become related party post-incorporation
  • Governmental approvals required: Incorporation according to laws of People's Democratic Republic of Algeria

Other Significant Information:

  • IMGSA Groupe SPA background: Algerian conglomerate founded in 2003 with presence in healthcare, real estate, agriculture
  • IMGSA turnover: US$ 100 Million for year ended December 2025 with 30% from exports
  • IMGSA export markets: Tunisia, Morocco, Yemen, Mauritania, Italy, Spain
  • Existing relationship: Beta has supplied semi-finished/finished formulations to IMGSA for 4 years
  • Beta supported IMGSA in oncology product registrations for Algeria market
  • Plant details: Equipped with production lines for Injectables and Oral Solid dosage forms, has been supplying to Algeria national tenders
  • Governance structure: Beta entitled to appoint 3 board members, IMGSA entitled to appoint 2 board members
  • Operational control: Beta to appoint CEO/General Manager and oversee day-to-day operations
  • Beta has affirmative voting rights over key governance matters including capital structure changes, capital expenditure, dissolution
  • Transaction subject to customary closing formalities
  • Board meeting duration: 9:00 a.m. to 10:50 a.m.